Keywords: Apixaban, Pfizer, Bristol-Myers Squibb, Phase III, Atrial fibrillation, Anti-clotting, Stroke

Early closing of apixaban trial on good results in AF sees Pfizer and Bristol-Myers Squibb shares rise

Article | 14 June 2010

Print This

US drug majors Pfizer and Bristol-Myers Squibb saw their share prices rise on Friday after announcing that they have agreed ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in